VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the first patient dosed in ...

NovaBridge Biosciences NBP shares are up on Monday following the announcement of positive topline results from the Phase 2a study of VIS-101, a treatment for retinal vascular diseases. Trial Data The ...

Neurotech Pharmaceuticals Inc., whose executive chairman is well-known Orange County executive Jim Mazzo, announced that it received FDA approval for its treatment of a type of macular telangiectasia ...

Retinopathy of prematurity (ROP) is one of the most common causes of severe visual impairment and blindness in children worldwide. Because the blood vessels in the retina are not fully developed, ...

Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...

The MarketWatch News Department was not involved in the creation of this content. -- Total potential deal value of $110 million plus royalties -- Kiora to receive an immediate $1.25 million exclusive ...